The invention discloses an application of
tiopronin wrapped by ROS (
reactive oxygen species) response hydrogel in preparation of a
medicine for treating
osteoarthritis. The ROS response hydrogel is prepared from the following components:
tiopronin; the compound group of
lecithin and ketal
thiol (TK) is TK-NH22, 2 '-(
propane-2, 2-diyl bis (
sulfanilamide diyl))
diethylamine (sulfanediyl), and the compound group of
lecithin and ketal
thiol (TK) is TK-NH22, 2'-(
propane-2, 2-diyl bis (
sulfanilamide diyl)); 12 wt% of
methyl cellulose, Na2HPO4. 12H2O and
xylitol; according to the hydrogel,
controlled release of
tiopronin is achieved through an ROS response group, mitochondrial
autophagy is enhanced by up-regulating a Bnip3-Pink1-Parkin
signal channel,
oxidative stress is inhibited, and the progress of
osteoarthritis is delayed; compared with the prior art, the invention has the advantages that: the invention discloses an
osteoarthritis treatment
medicine with the effects of resisting
inflammation, relieving pain and inhibiting
cartilage degeneration for the first time, and discloses a
knee joint intracavity administration
route of tiopronin for the first time. Particularly, the tiopronin targeted activation Bnip3-Pink1-Parkin
signal channel provided by the invention has a remarkable effect in the aspect of inhibiting the progress of OA, which proves that the
medicine has a strong effect on the treatment of osteoarthritis.